SCHEMBL5098532

SCHEMBL5098532

CC(=O)Nc1ccc(N)c(N2CCCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP2C19 P33261 2/20 0.59
GFER P55789 2/20 0.59
ALDH1A1 P00352 6/20 0.56
KDM4E B2RXH2 6/20 0.56
MAPT P10636 5/20 0.56
GAA P10253 4/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
MAPK1 P28482 3/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
S100B P04271 1/20 0.51
PKM P14618 1/20 0.51
ALOX15 P16050 1/20 0.51
TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5104848 0.83 GFER (0.56) CYP1A2CYP3A4CYP2C19GFERALDH1A1
SCHEMBL21163646 0.82 MAPT (0.59) CYP1A2CYP3A4CYP2C19GFERALDH1A1
SCHEMBL3543840 0.80 GAA (0.59) ALDH1A1KDM4EMAPTGAAMEN1
SCHEMBL7805753 0.79 MAPT (0.62) CYP1A2CYP3A4CYP2C19GFERALDH1A1
SCHEMBL5098076 0.79 MAPT (0.62) CYP1A2CYP3A4CYP2C19GFERALDH1A1
SCHEMBL26482564 0.78 KDM4E (0.54) GFERALDH1A1KDM4EMAPTGAA
SCHEMBL15714761 0.78 KDM4E (0.68) CYP1A2CYP3A4CYP2C19GFERALDH1A1
SCHEMBL7808036 0.77 MAPT (0.64) CYP1A2CYP3A4CYP2C19GFERALDH1A1
SCHEMBL3536868 0.77 GAA (0.68) ALDH1A1KDM4EMAPTGAAMEN1
SCHEMBL6689700 0.74 GFER (1.00) CYP1A2CYP3A4CYP2C19GFERALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP claimed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US claimed
US-7427683-B2 c-fms kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-09-23 US disclosed
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP disclosed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131022-A1 C-fms kinase inhibitors FLT3, FES, FGR CYP1A2 3681/4885CYP3A4 2705/4885CYP2C19 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.